How India Exports Ceftazidime to the World

In the United States, the Food and Drug Administration (FDA) oversees the approval and regulation of ceftazidime through the Abbreviated New Drug Application (ANDA) pathway. This process allows manufacturers to market generic versions of previously approved drugs, ensuring they meet stringent standards for bioequivalence, safety, and efficacy. The FDA's Orange Book provides a comprehensive list of approved drug products, including ceftazidime, detailing the number of approved ANDAs and their respective approval dates.

Importantly, the FDA maintains vigilance over imported pharmaceuticals to protect public health. The agency issues Import Alerts to identify products that may violate FDA regulations, leading to detention without physical examination (DWPE) of such products. As of March 2026, there are no active Import Alerts specifically targeting ceftazidime from Indian manufacturers, indicating compliance with FDA standards. However, with 228 active Indian exporters of ceftazidime, it is imperative for each to adhere strictly to FDA regulations to maintain market access.

In the European Union (EU) and the United Kingdom (UK), ceftazidime is subject to rigorous regulatory oversight. The European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) require that manufacturers obtain marketing authorization before distributing ceftazidime. This process involves a thorough evaluation of the drug's quality, safety, and efficacy. Additionally, compliance with Good Manufacturing Practice (GMP) standards is mandatory, ensuring that ceftazidime is consistently produced and controlled according to quality standards.

Ceftazidime is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in addressing priority health needs globally. The 24th edition of this list, published in September 2025, continues to recognize ceftazidime's critical role in treating severe bacterial infections. This inclusion serves as a guideline for countries to develop their own national essential medicines lists, promoting access to vital treatments. Furthermore, ceftazidime is listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and formulation across different regions.

In India, ceftazidime is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including ceftazidime, to ensure affordability. As of March 2026, the ceiling price for ceftazidime is set by the NPPA, reflecting the government's commitment to making essential medicines accessible. For exporters, obtaining a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) is a prerequisite, ensuring that exports comply with national regulations and do not compromise domestic availability.

Ceftazidime's primary patents have expired, allowing for the production and marketing of generic versions. This has led to increased competition among manufacturers, contributing to the drug's affordability and widespread availability. The absence of active patents facilitates the entry of multiple players into the market, promoting innovation and cost-effectiveness in production.

In the past 12 months, several key developments have impacted the ceftazidime market:

1. API Price Fluctuations (June 2025): The NPPA reported a 5% increase in the price of Active Pharmaceutical Ingredients (APIs) for ceftazidime, attributed to rising raw material costs.

2. Regulatory Approval (September 2025): The EMA granted marketing authorization for a new generic formulation of ceftazidime, expanding treatment options within the EU.

3. Policy Update (December 2025): The CDSCO revised guidelines for antibiotic manufacturing, emphasizing stricter compliance with GMP standards to enhance product quality.

4. Export Policy Change (February 2026): The DGFT introduced a streamlined process for obtaining export NOCs for antibiotics, including ceftazidime, to facilitate international trade.

5. WHO Prequalification (March 2026): A leading Indian manufacturer achieved WHO prequalification for its ceftazidime product, enhancing its credibility in global markets.

These developments reflect a dynamic regulatory environment and underscore the importance of continuous monitoring to navigate the complexities of the pharmaceutical industry effectively.

Ceftazidime, a third-generation cephalosporin antibiotic, is primarily produced in India and China. India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and intermediates, with approximately 70% of these imports originating from China. This dependency exposes the supply chain to risks associated with geopolitical tensions, trade restrictions, and environmental regulations in China.

In recent years, China's stringent environmental policies have led to the shutdown of several API manufacturing facilities, causing supply disruptions and increased costs. Such events underscore the vulnerability of India's pharmaceutical supply chain due to its reliance on Chinese KSMs.

Our proprietary trade data indicates that the top five Indian exporters of Ceftazidime account for 46.4% of total exports, with ZEISS PHARMACEUTICALS PRIVATE LIMITED leading at a 19.5% share. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could significantly impact global supply.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic production of critical APIs and reduce import dependence. The scheme has led to the establishment of new manufacturing units for essential molecules, potentially decreasing reliance on foreign sources.

Global shipping routes, including the Red Sea and the Strait of Hormuz, are susceptible to geopolitical tensions that can disrupt supply chains. Additionally, trade disputes, such as those between the U.S. and China, have previously led to tariff impositions and export restrictions, affecting the availability and cost of pharmaceutical ingredients. While specific FDA or EMA shortage alerts for Ceftazidime are not currently reported, the interconnected nature of global supply chains means that any disruption in these regions could have cascading effects on the availability of critical medications.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Leverage government incentives like the PLI scheme to invest in local manufacturing capabilities for critical pharmaceutical ingredients.

• Monitor Geopolitical Developments: Establish a dedicated team to track international events that could impact supply chains and develop contingency plans accordingly.

• Strengthen Regulatory Compliance: Ensure all suppliers adhere to international quality standards to prevent disruptions due to regulatory non-compliance.

• Develop Strategic Reserves: Maintain buffer stocks of essential APIs and KSMs to mitigate the impact of sudden supply chain disruptions.

RISK_LEVEL: MEDIUM